March 10, 2008

Gilead Sciences to Present at Two Upcoming Investor Conferences

Cowen and Company 28th Annual Healthcare Conference on March 17th Lehman Brothers 11th Annual Global Healthcare Conference on March 18th Webcasts Available Through Gilead Corporate Website

FOSTER CITY, Calif.--(BUSINESS WIRE)--March 10, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: Cowen and Company 28th Annual Healthcare Conference in Boston; and Lehman Brothers 11th Annual Global Healthcare Conference in Miami. These webcasts may be accessed via the company's corporate website at www.gilead.com.

John Martin, PhD, Gilead's President and Chief Executive Officer, will provide an overview of the company at the Cowen and Company conference on Monday, March 17 at 1:45 p.m. Eastern Time.

Kevin Young, Gilead's Executive Vice President of Commercial Operations, will provide an overview of the company at the Lehman Brothers conference on Tuesday, March 18 at 2:30 p.m. Eastern Time.

To access the live webcasts via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to each live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc. Patrick O'Brien, 650-522-1936 (Investor Relations) SOURCE: Gilead Sciences, Inc.

Other News

Some of the content on this page is not intended for users outside the U.S.